Recently, the guidance concerning Environmental Risk Assessment (ERA) for medicinal products came into effect in EU and the United States. On the other hand, from the view point of pharmaceutical industry, the question of how to handle the ERA is still open. The purpose of this paper is to note the difference between those tow guidance and propose the useful project model for pharmaceutical industry.
